A survival benefit has been demonstrated or is under investigation as the primary outcome among certain recently approved agents and investigational agents for men with metastatic castration-resistant prostate cancer that has spread to bone.
Written by:
McCain J. Are you the author?
Reference: P T. 2014 Feb;39(2):130-43.
PubMed Abstract
PMID: 24669181
UroToday.com Bone Metastases Section
